Evidence map›Paper›PMID 35925404›Full record

ArticleActa diabetologica2022

Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists.

Cristina Hernández, Fernando Gómez-Peralta, Olga Simó-Servat, Marta García-Ramírez, Cristina Abreu, Sara Gómez-Rodríguez, Rafael Simó

Abstract read
PubMed Publisher
In one paragraph

Article in Acta diabetologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Cristina Hernández *Department of Endocrinology, Vall d'Hebron University Hospital, Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Fernando Gómez-Peralta *Endocrinology and Nutrition Unit, Hospital General de Segovia, Segovia, Spain.
Olga Simó-ServatDepartment of Endocrinology, Vall d'Hebron University Hospital, Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Marta García-RamírezCentro de Investigación Biomédica en Red de Diabetes Y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ICSIII), Madrid, Spain.
Cristina AbreuEndocrinology and Nutrition Unit, Hospital General de Segovia, Segovia, Spain.
Sara Gómez-RodríguezEndocrinology and Nutrition Unit, Hospital General de Segovia, Segovia, Spain.
Rafael Simó *Department of Endocrinology, Vall d'Hebron University Hospital, Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain. rafael.simo@vhir.org.ORCID http://orcid.org/0000-0003-0475-3096
Hebron University · PSHospital General De Segovia · ESInstituto de Salud Carlos III · ES

Funding

Generalitat de Catalunya 2017SGR01144
6 · The paper itself

Abstract

aimsThe response to Glucagon-like peptide-1 receptor agonists (GLP-1RAs) is highly varia-ble among patients. Thus, the identification of predictive biomarkers of therapeutic response to GLP-1 RA could help us to optimize the use of this class of drugs. GLP-1RAs increase exchange proteins directly activated by cAMP (EPAC). The aim of the present study was to assess whether the increase of EPAC1 after GLP-1RAs treatment could be a biomarker of clinical response.

methodsAfter showing that GLP-1 (10 ng/mL) significantly increased the expression of EPAC1 in human endo-thelial vascular cells (HUVEC), a pilot clinical study was planned. For this purpose 49 patients with type 2 diabetes who started treatment with liraglutide were included. EPAC1 concentration was determined by ELISA before and at one month of liraglutide treatment.

resultsWe found that serum concentration of EPAC1 increased significantly after treatment with liraglutide. Only in those patients in whom EPAC1 increased (64%), a significant decrease in HbA1c, LDL-C, body mass index (BMI), and waist circumference was shown.

conclusionsThis pilot study suggests that the increase of circulating EPAC1 after GLP-1RAs treatment could be a useful biomarker to predict clinical GLP1-RAs response.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsBiomarkersCholesterol, LDLGlucagon-Like Peptide 1Glycated HemoglobinGuanine Nucleotide Exchange FactorsHumansHypoglycemic AgentsLiraglutidePilot ProjectsBiomarkersCholesterol, LDLGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinGuanine Nucleotide Exchange FactorsHypoglycemic AgentsLiraglutideClinical responseClinical studyExchange proteins di-rectly activated by campGlucagon-like peptide-1 receptor agonistsHuman endothelial vascular cellsType 2 diabetes

Identifiers

PMID35925404
OpenAlexW4289730844

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.